# EDGAR Filing Document

**Accession Number:** 0000055529
**File Stem:** 0000055529-26-000017
**Filing Date:** 2026-6
**Character Count:** 35662
**Document Hash:** c682dac854f86c444d8783da03a350c3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000055529-26-000017.hdr.sgml**: 20260623

**ACCESSION NUMBER**: 0000055529-26-000017

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20260623

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260623

**DATE AS OF CHANGE**: 20260623

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KEWAUNEE SCIENTIFIC CORP /DE/
- **CENTRAL INDEX KEY:** 0000055529
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY APPARATUS & FURNITURE [3821]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 380715562
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0430

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-05286
- **FILM NUMBER:** 261112074

**BUSINESS ADDRESS:**
- **STREET 1:** 2700 W FRONT ST
- **CITY:** STATESVILLE
- **STATE:** NC
- **ZIP:** 28677
- **BUSINESS PHONE:** 7048737202

**MAIL ADDRESS:**
- **STREET 1:** P O BOX 1842
- **CITY:** STATESVILLE
- **STATE:** NC
- **ZIP:** 28687-1842

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KEWAUNEE SCIENTIFIC EQUIPMENT CORP /DE/
- **DATE OF NAME CHANGE:** 19861216

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KEWAUNEE MANUFACTURING CO
- **DATE OF NAME CHANGE:** 19680108

?xml version='1.0' encoding='ASCII'? kequ-20260623

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 23, 2026**

**Kewaunee Scientific Corporation**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **0-5286** | **38-0715562** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(Commission File<br>Number)** | **(IRS Employer<br>Identification No.)** |

---

**2700 West Front Street**

**Statesville, NC 28677**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (704) 873-7202**

**N/A**

**(Former name or former address, if changed since last report)**

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, $2.50 par value** | **KEQU** | **The Nasdaq Global Market** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition**

On June 23, 2026, Kewaunee Scientific Corporation issued a press release announcing financial results for its fourth quarter and its fiscal year ended April 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d) Exhibits**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**<u>Exhibit No.</u>** | &nbsp;&nbsp;**<u>Description</u>** |
| &nbsp;&nbsp;99.1 | <u>[Press Release of Kewaunee Scientific Corporation dated June 2](prfy26q4earningsrelease.htm)[3](prfy26q4earningsrelease.htm)[, 202](prfy26q4earningsrelease.htm)[6](prfy26q4earningsrelease.htm)[.](prfy26q4earningsrelease.htm)</u> |
| &nbsp;&nbsp;104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

------

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | KEWAUNEE SCIENTIFIC CORPORATION<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Registrant) | KEWAUNEE SCIENTIFIC CORPORATION<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Registrant) |
| Date: June 23, 2026 | By | /s/ Donald T. Gardner III |
| | | Donald T. Gardner III |
| | | Executive Vice President, Finance |
| | | Chief Financial Officer |

---

## Exhibit 99.1

![logo_stackedxdark.jpg](logo_stackedxdark.jpg)

**Kewaunee Scientific Reports**

**Results for Fiscal Year and Fourth Quarter**

Exchange:&nbsp;&nbsp;&nbsp;&nbsp;NASDAQ (KEQU)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contact:&nbsp;&nbsp;&nbsp;&nbsp;Donald T. Gardner III

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;704/871-3274

STATESVILLE, N.C. June 23, 2026 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its fiscal year and fourth quarter ended April 30, 2026.

**<u>Fiscal Year 2026 Full Year Results</u>**

Fiscal year 2026 was highlighted by strong revenue, continued progress integrating Nu Aire, and significant balance sheet improvement, despite a challenging operating environment.

Sales during fiscal year 2026 were $281,999,000, an increase of 17.3% compared to sales of $240,472,000 from the prior year. Pre-tax earnings for the fiscal year were $13,733,000 compared to pre-tax earnings of $14,785,000 for the prior year. Net earnings for the fiscal year were $9,618,000, compared to net earnings of $11,405,000 for the prior year. Diluted earnings per share was $3.22, as compared to diluted earnings per share of $3.83 in the prior fiscal year. EBITDA<sup>1</sup> for the fiscal year was $22,425,000, compared to $21,613,000 for the prior fiscal year.

During fiscal year 2026, the Company renamed its Domestic reportable segment to Lab Products Group ("LPG") to better align with the segment's expanded business activities, organizational structure, and strategic direction. The segment name change had no impact on the composition of the Company's reportable segments or on previously reported financial position, results of operations, cash flows, or segment operating results.

**Fiscal Year Segment Results and Discussion:**

**<u>Lab Products Group Segment</u>** - LPG sales for the fiscal year were $214,886,000, an increase of 19.8% from sales of $179,398,000 in the prior year. LPG segment net earnings were $14,156,000 compared to $15,370,000 in the prior fiscal year. LPG segment EBITDA was $25,059,000 compared to $25,580,000 for the prior year. Lab Products Group segment results for fiscal year 2026 reflected solid execution and the perseverance of the Company's expanded domestic platform. The laboratory construction portion of the business faced challenging market conditions throughout the year, including volatility in project delivery timelines, lower manufacturing volumes during certain periods, higher input costs, and tariff-related cost pressure. These headwinds were partially mitigated by the team's continued productivity improvements, disciplined cost controls, proactive production scheduling, and further enhancement of the Company's strong operating foundation. The addition of Nu Aire also added breadth to the Company's laboratory products portfolio. The segment's performance underscores

<sup>1</sup> EBITDA, Adjusted EBITDA, adjusted net earnings, and adjusted net earnings per share are non-GAAP financial measures. See the tables below for a reconciliation of these non-GAAP measures to the most comparable GAAP measures.

CORPORATE OFFICES ● P. O. BOX 1842, STATESVILLE, NORTH CAROLINA 28687-1842 ● 2700 WEST FRONT STREET, STATESVILLE, NORTH CAROLINA 28677-2927

PHONE 704-873-7202 ● FAX 704-873-1275

------

the value of the Company's broader laboratory products portfolio and its strategy to diversify revenue and earnings streams across the domestic business.

**<u>International Segment</u>** - International sales for the fiscal year were $67,113,000, an increase of 9.9% from sales of $61,074,000 in the prior year. International segment net earnings were $4,023,000 compared to $2,902,000 in the prior fiscal year. International segment EBITDA was $5,933,000 compared to $4,475,000 for the prior year. International segment results for fiscal year 2026 demonstrated the resilience of the Company's international business and the strength of its project backlog. In a year marked by significant geopolitical uncertainty, including the conflict in the Middle East and its broader effects on regional business conditions, the segment delivered year-over-year growth in sales, net earnings, and EBITDA. These results were supported by disciplined project execution and excellent performance by the International team, which effectively managed through customer timing shifts, logistical complexity, and evolving market conditions. The segment's performance underscores the durability of demand for the Company's turnkey laboratory solutions across the Indian and greater Asian markets.

**<u>Corporate Segment</u>** - Corporate segment net loss was ($8,561,000) for the fiscal year, as compared to ($6,867,000) in the prior fiscal year. Corporate segment EBITDA loss for the fiscal year was ($8,567,000) as compared to Corporate segment EBITDA loss of ($8,442,000) for the prior year. Corporate segment results for fiscal year 2026 reflected the Company's continued investment in the Corporate platform required to support a larger public company and execute its long-term growth strategy. Corporate segment EBITDA loss remained relatively consistent with the prior fiscal year, despite continued strategic investments in people, processes, systems, technology, compliance capabilities, and operating infrastructure. These investments are intended to strengthen the Company's scalability, support future acquisition integration, and enable continued execution of its organic and inorganic growth strategy.

**Consolidated Working Capital Discussion:**

The Company continued to strengthen its balance sheet during fiscal year 2026, reducing long-term debt by approximately $20 million and completing repayment of the Seller Notes incurred in connection with the Nu Aire acquisition. As a result, the Company's debt-to-equity ratio improved to 0.61-to-1 from 0.99-to-1 in the prior year.

Total cash on hand on April 30, 2026 was $11,617,000, as compared to $17,164,000 on April 30, 2025. The decrease in cash was primarily driven by the successful completion of the Company's Seller Note Repayment in December 2025. Working capital was $57,046,000 on April 30, 2026, as compared to $64,651,000 on April 30, 2025.

The Company had short-term debt of $5,904,000 as of April 30, 2026, as compared to $4,773,000 on April 30, 2025. Long-term debt was $40,851,000 on April 30, 2026, as compared to $60,730,000 on April 30, 2025. The building lease from the Company's December 2021 sale-leaseback transaction accounts for $25,765,000 of the long-term debt on April 30, 2026 and $26,632,000 of the long-term debt on April 30, 2025. Long-term debt, net of the sale-leaseback transaction, was $15,086,000 on April 30, 2026 as compared to $34,098,000 on April 30, 2025. The Company's debt-to-equity ratio, net of the sale-leaseback transaction, on April 30, 2026 was 0.26-to-1, as compared to 0.57-to-1 on April 30, 2025.

The Company ended fiscal year 2026 with order backlog of $165.9 million, including $118.8 million within the Lab Products Group and $47.1 million within the International segment. Lab Products Group backlog increased from $114.9 million at January 31, 2026 and decreased compared to $123.9 million on April 30, 2025. International backlog decreased compared to $68.3 million on January 31, 2026 and $90.7 million on April 30, 2025, reflecting the timing of project shipments and awards and the cancellation of two projects in India.

------

"Fiscal year 2026 was an excellent year for Kewaunee, particularly in light of the challenging operating environment in which it was delivered," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "Our team managed through these conditions effectively, maintaining a strong level of EBITDA while making meaningful progress on the strategic priorities that will support Kewaunee's next phase of growth. We continued to invest in the Corporate platform required to scale as a public company, support future acquisitions, and accelerate our organic and inorganic growth strategy. We also made significant progress integrating Nu Aire, positioning the business for improved performance as life sciences market conditions recover, while strengthening our balance sheet through the servicing and repayment of acquisition-related debt."

"The launch of Kewaunee's Lab Products Group represents an important strategic milestone, combining Kewaunee and Nu Aire's world-class product portfolios into a broader and more comprehensive offering for customers," Hull continued. "We also strengthened our international leadership with the addition of Jorge Santos, further enhancing our ability to grow and serve customers globally."

"As we enter fiscal 2027, Kewaunee is well positioned to continue executing its growth strategy. We remain focused on disciplined capital allocation, operational execution, and serving our customers with excellence. I believe we have the best team in the industry, and I am incredibly proud of what they accomplished this year. Their performance reinforces my confidence in Kewaunee's ability to create durable long-term value for our shareholders."

**<u>Fiscal Year 2026 Fourth Quarter Results</u>**

Sales during the fourth quarter of fiscal year 2026 were $71,400,000, a decrease of 7.5% compared to sales of $77,148,000 from the prior year's fourth quarter. Pre-tax earnings for the quarter were $4,756,000 compared to $7,149,000 for the prior year quarter. Net earnings for the quarter were $3,388,000 compared to net earnings of $4,850,000 for the prior year quarter. Diluted earnings per share were $1.13 compared to diluted earnings per share of $1.63 in the prior year quarter. EBITDA for the quarter was $6,520,000 compared to $9,671,000 for the prior year quarter.

**Fourth Quarter Segment Results and Discussion:**

**<u>Lab Products Group Segment</u>** - LPG sales for the quarter were $54,357,000, a decrease of 2.0% from sales of $55,490,000 in the prior year quarter. LPG segment net earnings were $3,547,000 compared to $5,099,000 in the prior year quarter. LPG segment EBITDA was $6,674,000 compared to $8,755,000 for the prior year quarter. LPG segment profitability was impacted during the fourth quarter by lower manufacturing volumes across the laboratory construction portion of the business, reflecting continued volatility in project delivery timelines. The Company continued to actively manage production schedules, productivity, and costs in response to these timing dynamics.

**<u>International Segment</u>** - International sales for the quarter were $17,043,000, a decrease of 21.3% from sales of $21,658,000 in the prior year quarter. International segment net earnings were $1,483,000 compared to $1,607,000 in the prior year quarter. International segment EBITDA was $2,055,000 compared to $2,427,000 for the prior year quarter. International segment profitability was slightly lower when compared to the prior year period, driven by lower billings. The decrease was principally related to shipment timing for projects in the Middle East, where deliveries continue to be affected by regional geopolitical disruption.

**<u>Corporate Segment</u>** - Corporate segment net loss was ($1,642,000) for the quarter, as compared to ($1,856,000) in the prior year quarter. Corporate segment EBITDA loss for the quarter was ($2,209,000) compared to corporate segment EBITDA loss of ($1,511,000) for the prior year quarter. Corporate segment EBITDA loss in the current year quarter reflects the Company's

------

continued strategic investments in people, processes, and technology to further build out its Corporate platform and support it's long-term growth strategy.

"We closed out the fiscal year with a solid fourth quarter," said Hull. "In our Lab Products Group segment, project timing continued to pressure manufacturing volumes in the laboratory construction portion of the business. Internationally, lower billings, particularly related to shipment timing in the Middle East, modestly pressured profitability. I am proud of the resilience and skill Kewaunee's global team showed in navigating these headwinds."

------

**<u>EBITDA and Segment EBITDA Reconciliation</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Quarter Ended April 30, 2025** | **LPG** | **International** | **Corporate** | **Consolidated** |
| Net Earnings (Loss) | $5099 | $1607 | $(1856) | $4850 |
| Add/(Less): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest Expense | 316 | 5 | 842 | 1163 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest Income |  | (113) | (6) | (119) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income Taxes | 1910 | 825 | (533) | 2202 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and Amortization | 1430 | 103 | 42 | 1575 |
| EBITDA | $8755 | $2427 | $(1511) | $9671 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional and Other Fees<sup>2</sup> | 514 |  | 136 | 650 |
| Adjusted EBITDA | $9269 | $2427 | $(1375) | $10321 |
| **Quarter Ended April 30, 2026** | **LPG** | **International** | **Corporate** | **Consolidated** |
| Net Earnings (Loss) | $3547 | $1483 | $(1642) | $3388 |
| Add/(Less): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest Expense | 305 | 12 | 314 | 631 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest Income | (2) | (116) |  | (118) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income Taxes | 1347 | 616 | (899) | 1064 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and Amortization | 1477 | 60 | 18 | 1555 |
| EBITDA | $6674 | $2055 | $(2209) | $6520 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional and Other Fees<sup>3</sup> |  |  | 22 | 22 |
| Adjusted EBITDA | $6674 | $2055 | $(2187) | $6542 |
| **Fiscal Year to Date April 30, 2025** | **LPG** | **International** | **Corporate** | **Consolidated** |
| Net Earnings (Loss) | $15370 | $2902 | $(6867) | $11405 |
| Add/(Less): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest Expense | 1492 | 71 | 1651 | 3214 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest Income | (1) | (550) | (416) | (967) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income Taxes | 4553 | 1632 | (2983) | 3202 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and Amortization | 4166 | 420 | 173 | 4759 |
| EBITDA | $25580 | $4475 | $(8442) | $21613 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional and Other Fees<sup>2</sup> | 1526 |  | 3389 | 4915 |
| Adjusted EBITDA | $27106 | $4475 | $(5053) | $26528 |
| **Fiscal Year to Date April 30, 2026** | **LPG** | **International** | **Corporate** | **Consolidated** |
| Net Earnings (Loss) | $14156 | $4023 | $(8561) | $9618 |
| Add/(Less): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest Expense | 1236 | 51 | 2575 | 3862 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest Income | (6) | (544) | (54) | (604) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income Taxes | 3830 | 2051 | (2613) | 3268 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and Amortization | 5843 | 352 | 86 | 6281 |
| EBITDA | $25059 | $5933 | $(8567) | $22425 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional and Other Fees<sup>3</sup> |  |  | 785 | 785 |
| Adjusted EBITDA | $25059 | $5933 | $(7782) | $23210 |

---

<sup>2</sup> Professional and other fees incurred during the three months and fiscal year ended April 30, 2025 related to the acquisition of Nu Aire, Inc. ("Nu Aire"), which closed on November 1, 2024, and related purchase accounting

<sup>3</sup> Professional and other fees incurred during the three months and fiscal year ended April 30, 2026 related to the Company's integration of its newly acquired subsidiary, Nu Aire

------

**<u>Adjusted Consolidated Statement of Operations Reconciliation</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>April 30,** | **Three Months Ended<br>April 30,** | **Three Months Ended<br>April 30,** | **Three Months Ended<br>April 30,** |
| | **As Reported 2026** | **Professional and Other Fees**<sup>4</sup> | **Adjusted<br>2026** | **Adjusted<br>2025** |
| Net sales | $**71400** | $**—** | $**71400** | $77148 |
| Cost of products sold | **50155** | **—** | **50155** | 52424 |
| Gross profit | **21245** | **—** | **21245** | 24724 |
| Operating expenses | **16029** | **22** | **16007** | 14966 |
| Operating profit | **5216** | **22** | **5238** | 9758 |
| Other income (expense), net | **171** | **—** | **171** | (188) |
| Interest expense | **(631)** | **—** | **(631)** | (1163) |
| Profit before income taxes | **4756** | &nbsp;&nbsp;**22** | **4778** | 8407 |
| Income tax expense | **1064** | **6** | **1070** | 2496 |
| Net earnings | **3692** | &nbsp;&nbsp;&nbsp;**16** | **3708** | 5911 |
| Less: Net earnings attributable to the non-controlling interest | **304** | **—** | **304** | 97 |
| Net earnings attributable to Kewaunee Scientific Corporation | $**3388** | $**16** | $**3404** | $5814 |
| Net earnings per share attributable to Kewaunee Scientific Corporation stockholders |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $**1.18** | $**0.01** | $**1.19** | $2.04 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $**1.13** | $**0.01** | $**1.14** | $1.95 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Twelve Months Ended<br>April 30,** | **Twelve Months Ended<br>April 30,** | **Twelve Months Ended<br>April 30,** | **Twelve Months Ended<br>April 30,** |
| | **As Reported 2026** | **Professional and Other Fees**<sup>4</sup> | **Adjusted<br>2026** | **Adjusted<br>2025** |
| Net sales | $**281999** | $**—** | $**281999** | $240472 |
| Cost of products sold | **201559** | **—** | **201559** | 170075 |
| Gross profit | **80440** | **—** | **80440** | 70397 |
| Operating expenses | **63725** | **785** | **62940** | 46920 |
| Operating profit | **16715** | **785** | **17500** | 23477 |
| Other income, net | **880** | **—** | **880** | 564 |
| Interest expense | **(3862)** | **—** | **(3862)** | (3214) |
| Profit before income taxes | **13733** | **785** | **14518** | 20827 |
| Income tax expense | **3268** | **180** | **3448** | 4657 |
| Net earnings | **10465** | **605** | **11070** | 16170 |
| Less: Net earnings attributable to the non-controlling interest | **847** | **—** | **847** | 178 |
| Net earnings attributable to Kewaunee Scientific Corporation | $**9618** | $**605** | $**10223** | $15992 |
| Net earnings per share attributable to Kewaunee Scientific Corporation stockholders |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $**3.36** | $**0.21** | $**3.57** | $5.59 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $**3.22** | $**0.20** | $**3.43** | $5.37 |

---

<sup>4</sup> Professional and other fees incurred during the three months and fiscal year ended April 30, 2026 related to the Company's integration of its newly acquired subsidiary, Nu Aire

------

*About Non-GAAP Measures* 

The Company includes non-GAAP financial measures such as adjusted net earnings and adjusted net earnings per share, in the information provided with this press release as supplemental information relating to its operating results. Adjusted net earnings represents GAAP net earnings adjusted for professional and other fees related to the integration and acquisition of Nu Aire, Inc. and the corresponding tax impact in fiscal years 2026 and 2025, respectively. This financial information is not in accordance with, or an alternative for, GAAP-compliant financial information and may be different from the operating or non-GAAP financial information used by other companies. The Company believes that this presentation of adjusted net earnings and adjusted net earnings per share provides useful information to investors regarding certain additional financial and business trends relating to its financial condition and results of operations.

EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. Adjusted EBITDA and Adjusted Segment EBITDA are calculated as EBITDA or Segment EBITDA less the impact of the one-time costs incurred for professional and other fees related to the integration and acquisition of Nu Aire, Inc. during fiscal years 2026 or 2025, respectively, as discussed in more detail above. We believe EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to depreciation and amortization or the costs incurred related to the integration and acquisition of Nu Aire, Inc. during fiscal years 2026 and 2025, respectively, which can vary significantly between companies depending upon many factors. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA can vary among companies. The amounts included in the EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA calculations, however, are derived from amounts included in the historical consolidated statements of operations. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company's operating performance, or as an alternative to operating cash flows as a measure of liquidity.

*About Kewaunee Scientific* 

Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's portfolio includes laboratory casework, fume hoods, adaptable modular systems, healthcare storage solutions, epoxy resin work surfaces and sinks, biological safety cabinets, and other critical containment lab furniture solutions.

The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, Spain, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets. The Company also operates manufacturing facilities in Plymouth and Long Lake, Minnesota, and maintains warehouse partnerships in the Netherlands and OEM partnerships in China through its acquisition of Nu Aire, Inc., supporting customers around the world.

Learn more at at <u>http://www.kewaunee.com.</u> 

*This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate,"* 

------

*"estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the most recent fiscal year ended April 30, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at <u>www.kewaunee.com</u> and on the SEC website at <u>www.sec.gov</u>. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.*

------

**Kewaunee Scientific Corporation**

**Condensed Consolidated Statements of Operations**

*($ and shares in thousands, except per share amounts)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>April 30,** | **Three Months Ended<br>April 30,** | **Twelve Months Ended<br>April 30,** | **Twelve Months Ended<br>April 30,** |
| | **2026** | **2025** | **2026** | **2025** |
| Net sales | $**71400** | $77148 | $**281999** | $240472 |
| Cost of products sold | **50155** | 53110 | **201559** | 171615 |
| Gross profit | **21245** | 24038 | **80440** | 68857 |
| Operating expenses | **16029** | 15538 | **63725** | 51098 |
| Operating profit | **5216** | 8500 | **16715** | 17759 |
| Other income (expense), net | **171** | (188) | **880** | 240 |
| Interest expense | **(631)** | (1163) | **(3862)** | (3214) |
| Profit before income taxes | **4756** | 7149 | **13733** | 14785 |
| Income tax expense | **1064** | 2202 | **3268** | 3202 |
| Net earnings | **3692** | 4947 | **10465** | 11583 |
| Less: Net earnings attributable to the non-controlling interest | **304** | 97 | **847** | 178 |
| Net earnings attributable to Kewaunee Scientific Corporation | $**3388** | $4850 | $**9618** | $11405 |
| Net earnings per share attributable to Kewaunee Scientific Corporation stockholders |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $**1.18** | $1.70 | $**3.36** | $3.98 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $**1.13** | $1.63 | $**3.22** | $3.83 |
| Weighted average number of common shares outstanding |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | **2866** | 2854 | **2863** | 2862 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | **2995** | 2981 | **2983** | 2979 |

---

------

**Kewaunee Scientific Corporation**

**Condensed Consolidated Balance Sheets**

*($ in thousands)*

---

| | | |
|:---|:---|:---|
| | **April 30, 2026** | **April 30, 2025** |
| **<u>Assets</u>** | | |
| Cash and cash equivalents | $**9950** | $**14942** |
| Restricted cash | **1667** | **2222** |
| Receivables, less allowances | **58738** | **62384** |
| Inventories | **30533** | **32849** |
| Prepaid expenses and other current assets | **4509** | **5966** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets | **105397** | **118363** |
| Net Property, Plant and Equipment | **22367** | **23174** |
| Right of use assets | **10791** | **12965** |
| Deferred income taxes | **3829** | **3994** |
| Intangible assets, net | **16294** | **17831** |
| Goodwill | **12487** | **12487** |
| Other assets | **7146** | **5840** |
| Total Assets | $**178311** | $**194654** |
| **<u>Liabilities and Stockholders' Equity</u>** |  |  |
| Short-term borrowings | $**74** | $**986** |
| Current portion of term loans | **4893** | **2903** |
| Current portion of lease obligations | **3845** | **3371** |
| Current portion of financing liability | **867** | **788** |
| Accounts payable | **22455** | **27033** |
| Other Current Liabilities | **16217** | **18631** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities | **48351** | **53712** |
| Long-term portion of lease obligations | **6569** | **8946** |
| Long-term portion of financing liability | **25765** | **26632** |
| Long-term portion of seller note | **—** | **23537** |
| Long-term portion of term loans | **14804** | **10412** |
| Other non-current liabilities | **6010** | **5170** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities | **101499** | **128409** |
| Commitments and Contingencies |  |  |
| Stockholders' Equity: |  |  |
| Kewaunee Scientific Corporation Equity | **74718** | **64457** |
| Non-controlling interest | **2094** | **1788** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Stockholders' Equity | **76812** | **66245** |
| Total Liabilities and Stockholders' Equity | $**178311** | $**194654** |

---

<br>